This is a valid question and unfortunately I canno

This is a valid question and unfortunately I cannot answer it. For an unknown reason, NP felt CYDY should own the EIND data and not Incelldx. Does this have to do with a patent regarding the the pathways and a treatment and/or laboratory? I’m not a patent lawyer, so I’m unsure if you can patent a specific treatment pathway, but I’m sure you can patent certain laboratory tests for that pathway.

So, again, I don’t see the benefit of NP blocking the ownership of the EIND data, especially when you consider CYDY was planning two trials at the time (M2M and S/C) that could produce even more data.